Teleflex Q2 Earnings Call Highlights
Key Points
- Interested in Teleflex Incorporated? Here are five stocks we like better.
- Teleflex exceeded Q2 expectations, with revenue of $570.3 million, adjusted EPS of $1.76 and strong growth in its Vascular and Surgical segments. Interventional revenue declined 1% as acquisition integration disrupted systems, distributors and sales-force operations.
- The company lowered its 2026 revenue-growth outlook to 3.5%–4.5% but raised adjusted EPS guidance to $6.90–$7.20, helped by share repurchases and lower interest expense. Management expects Interventional integration to be completed by year-end and described 2026 as a transition year.
- Teleflex is using divestiture proceeds to reduce debt and return capital, including $250 million of Q2 share repurchases and another planned $250 million accelerated buyback. The company also highlighted FDA approval for EZPLAZ plasma and continued progress on its Freesolve scaffold program.
Teleflex (NYSE:TFX) reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated integration of its acquired Vascular Intervention business weighed on Interventional results.
Revenue from continuing operations totaled $570.3 million in the second quarter, up 28.9% on a GAAP basis and 4.7% on a pro forma adjusted constant-currency basis. Adjusted earnings per share rose 1.7% year over year to $1.76. Adjusted operating margin was 19.6%.
President and CEO Jason Weidman, who said he has spent his first two months visiting sites, meeting employees and customers, and reviewing the portfolio, said the company is focused on completing divestitures, reducing debt, repurchasing shares and addressing stranded costs. He described 2026 as a transition year and said the company expects a “meaningful step-up” in financial performance in 2027 and beyond.
Segment Performance
Vascular revenue increased 8% year over year to $246.3 million, driven primarily by hemostatic products and the central access portfolio. Surgical revenue rose 9.2% to $112.1 million, led by ligation clips, instruments and skin staplers.
Interventional revenue declined 1% to $211.9 million. While hemostatic products, right-heart catheters, intraosseous products and complex catheters outperformed, Weidman said the business was affected by continuing integration and restructuring activity following the Vascular Intervention acquisition.
Weidman said the issues were not product-related and identified three main transition areas: order-to-cash system changes, distributor transitions and sales-force realignment. He said the acquired BIOTRONIK Vascular Intervention revenue base was disproportionately affected by the disruption.
The company had initially expected the integration to be largely completed around the middle of 2026, but now expects full integration to extend through the second half. Weidman said Teleflex has mitigation plans in place and has “really good confidence” it can work through the issues by year-end, although sales-force ramping will occur gradually as new hires and training progress.
Management said Vascular and Surgical are expected to continue performing solidly in the second half, though at more moderate growth rates than in the first half. Teleflex cited some inventory buildup at major Vascular distributors and tougher comparisons in Surgical, particularly in its instrument portfolio. The company said it has not seen an impact from broader procedure-volume trends or from the expiration of Affordable Care Act subsidies.
Divestitures, Debt Reduction and Buybacks
Teleflex completed the sale of its OEM business during the quarter, generating approximately $1.5 billion in proceeds, or an estimated $1.25 billion after tax. The company used a portion of the proceeds to repay the $700 million Term Loan A-2 associated with its Vascular Intervention acquisition.
The company remains committed to its previously announced plan to reduce debt by $800 million and return $1 billion to shareholders through share repurchases. During the second quarter, Teleflex repurchased about 1.9 million shares for $250 million in open-market purchases, at an average price of $130.85 per share.
Teleflex also said it intends to begin an additional $250 million accelerated share repurchase on Aug. 7. Management said it expects the remaining $500 million of its repurchase plan to be funded largely with proceeds from the pending sale of its Acute Care and Interventional Urology businesses.
That transaction remains expected to close in the fourth quarter of 2026, subject to regulatory approval and other closing conditions. The Federal Trade Commission issued a second request for information in March, and Teleflex said both parties are cooperating with the review.
Net leverage was about 2.8 times at the end of the second quarter, while pro forma net leverage following the OEM divestiture was about 1.9 times, according to CFO John Deren.
Updated 2026 Outlook
Teleflex lowered its full-year outlook for pro forma adjusted constant-currency revenue growth to 3.5% to 4.5%, from its prior range of 4.5% to 5.5%. The reduction reflects first-half performance and the longer timeline for Interventional integration.
Weidman said the lower end of the range assumes no improvement in Interventional revenue from second-quarter levels for the remainder of the year, along with typical third-quarter seasonality.
- Adjusted EPS guidance was raised to $6.90 to $7.20, from $6.25 to $6.55.
- Adjusted operating margin is still expected to be approximately 19% for 2026.
- Full-year net interest expense is now expected to be about $85 million, down from a prior estimate of about $105 million.
- The adjusted tax rate is expected to be approximately 12.25%, compared with the prior outlook of roughly 13.5%.
Deren said the higher earnings outlook reflects second-quarter share repurchases and lower expected interest expense. Guidance does not include potential benefits from the pending Acute Care and Interventional Urology sale, additional second-half repurchases beyond the announced accelerated program, or tariff refunds.
The company expects about $39 million in tariff refunds in cash overall, according to Deren, though the timing remains uncertain. Teleflex said approximately $15 million related to 2026 tariffs recorded in the first half could be recognized in earnings once confirmed by the U.S. government.
Innovation Programs
Teleflex highlighted recent progress in its innovation pipeline. The FDA granted biologics license approval in late July for EZPLAZ Freeze-Dried Plasma, which is approved for adults with uncontrolled traumatic bleeding when plasma is required and other plasma products are unavailable. The product is designed for use in settings such as battlefields and air or road ambulances, where traditional plasma products can face logistical constraints.
Weidman said Teleflex’s immediate priority for EZPLAZ is the U.S. government and military market. He expects any 2026 revenue to be immaterial but said the product should contribute in 2027.
The company also advanced its Freesolve drug-eluting resorbable magnesium scaffold program. Teleflex completed enrollment ahead of schedule for the BIOMAG-II randomized trial outside the U.S., with a data readout expected in late 2027. It also initiated the U.S. BIOMAG-III pivotal trial, with the first patient procedures completed in June.
Weidman said the company is encouraged by early clinical data and views Freesolve as a potential option in coronary and endovascular procedures that seek to “leave nothing behind.”
About Teleflex (NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.
The company's offerings span several key segments, including Interventional Urology, Respiratory Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Source MarketBeat
